Abstract: A liquid delivery device includes a liquid delivery pump that sucks a mobile phase, which is liquid, from a mobile phase container containing the mobile phase through a suction pipe whose end is immersed in the mobile phase in the mobile phase container, and feeds the mobile phase, and at least one dissolved substance removal filter that is provided at a position upstream of the liquid delivery pump on a path through which the mobile phase flows and is filled with a filler having the property of adsorbing a dissolved substance in the mobile phase.

Abstract: A liquid delivery device includes a liquid delivery pump that sucks a mobile phase, which is liquid, from a mobile phase container containing the mobile phase through a suction pipe whose end is immersed in the mobile phase in the mobile phase container, and feeds the mobile phase, and at least one dissolved substance removal filter that is provided at a position upstream of the liquid delivery pump on a path through which the mobile phase flows and is filled with a filler having the property of adsorbing a dissolved substance in the mobile phase.

Abstract: A injection-needle cover includes an injection needle enclosure portion, which has paired base-side wall portions, a cylinder portion, paired tip-end-side wall portions, an injection needle contact portion, a hook portion, and a needle tip end fixing portion. The injection needle contact portion is disposed at a position in a base-side axial space, which is a boundary between the base-side axial space and an intra-cylinder space. The injection needle contact portion has a force receiving portion and a connecting portion. The force receiving portion receives a force from the injection needle when the force receiving portion comes in contact with the injection needle. The force receiving portion has an easy sliding portion, which is disposed in an area adjacent to an injection needle, and slides more easily along the injection needle than a case where an edge slides along the injection needle.

Abstract: A injection-needle cover includes an injection needle enclosure portion, which has paired base-side wall portions, a cylinder portion, paired tip-end-side wall portions, an injection needle contact portion, a hook portion, and a needle tip end fixing portion. The injection needle contact portion is disposed at a position in a base-side axial space, which is a boundary between the base-side axial space and an intra-cylinder space. The injection needle contact portion has a force receiving portion and a connecting portion. The force receiving portion receives a force from the injection needle when the force receiving portion comes in contact with the injection needle. The force receiving portion has an easy sliding portion, which is disposed in an area adjacent to an injection needle, and slides more easily along the injection needle than a case where an edge slides along the injection needle.

Abstract: In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.

Abstract: In a production process of granules containing a biologically active substance, variation in the elation profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent fox a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 more, the variation in the elution profile of the biologically active substance from the granules is reduced.

Abstract: In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.

Abstract: Four stochastic resonators 20-1 to 20-4 outputting a pulse signal in accordance with a stochastic resonance phenomenon are unidirectionally coupled in a ring-like form to constitute a fluctuation oscillator 10. When a signal output from each of the stochastic resonators 20-1 to 20-4 is successively transmitted in the stochastic resonators 20-1 to 20-4 coupled in a ring-like form, the output timings at each stochastic resonator 20 are synchronized with each other due to a cooperation phenomenon between the stochastic resonators 20-1 to 20-4, so that each stochastic resonator 20 is self-excited to oscillate at a constant period of time.

Abstract: Four stochastic resonators 20-1 to 20-4 outputting a pulse signal in accordance with a stochastic resonance phenomenon are unidirectionally coupled in a ring-like form to constitute a fluctuation oscillator 10. When a signal output from each of the stochastic resonators 20-1 to 20-4 is successively transmitted in the stochastic resonators 20-1 to 20-4 coupled in a ring-like form, the output timings at each stochastic resonator 20 are synchronized with each other due to a cooperation phenomenon between the stochastic resonators 20-1 to 20-4, so that each stochastic resonator 20 is self-excited to oscillate at a constant period of time.

Abstract: The present invention provides an emulsion composition comprising (A) a compound stable in an acidic range, and (B) a buffer, wherein the pH is adjusted from about 3.7 to about 5.5.

Abstract: The present invention provides a bilayer dispersing agent for a sustained-release preparation, which contains a non water-soluble solvent and an aqueous solvent, and a sustained-release preparation wherein a microcapsule containing a physiologically active substance is dispersed in the aforementioned dispersing agent. When this preparation is subcutaneously administered, the initial release of a physiologically active substance immediately after administration is strikingly suppressed, a constant amount of a physiologically active substance is released for a long period of time from immediately after administration, superior dispersibility is afforded, and the preparation can readily pass through a needle as an injection.

Abstract: An injectable composition comprises a benzimidazole compound having an antiulcer action and a strong alkali (e.g., an alkali metal hydroxide such as sodium hydroxide) in a proportion of about 1 equivalent of the latter relative to 1 mol of the former, and is substantially free from a nonaqueous solvent. The injectable composition may comprise N-methylglucamine, and a saccharide (such as mannitol). The injectable composition may be a freeze-dried preparation. The freeze-dried preparation is dissolvable in or dilutive with a distilled water for injection or an infusion solution without a nonaqueous solvent. The injectable composition is useful as an antiulcer agent.

Abstract: An elution test method measures the elution process of a specific component in a process where a preparation containing at least the specific component subject to a change with time in chemical properties after elution and an impurity component not subject to a change with time in chemical properties after elution is eluted into a test liquid. The method obtains a ratio of absorbance k of the impurity component and a ratio of absorbance k? of the specific component at two isosbestic point wavelengths ?1, ?2 in a spectrum including the specific component and its decomposed matter, and calculates at least one of the absorbances A1(t), A2(t) of said specific component by using k×C2(t)?C1(t)=k×A2(t)?A1(t) and A1(t)/A2(t)=k? from the absorbance C1(t), C2(t) at said two isosbestic point wavelengths ?1, ?2 measured at the plural time points t in the elution process of said preparation, and converts the result to an elution concentration.

Abstract: In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.

Abstract: The present invention relates to a pharmaceutical composition containing a cycloalkene compound, a salt thereof or a prodrug thereof, and a nonionic surfactant and/or a cyclodextrin derivative readily soluble in water, and a method for improving solubility, stability or coloring property of the compound, a salt thereof or a prodrug thereof.

Abstract: Device for improving detection sensitivity in low flow velocity high performance liquid chromatographic apparatus. Preferredly, diffusion promoting device connected at just before separation column and having function of improving detection sensitivity for use in low flow velocity high performance liquid chromatographic apparatus. Also, method for improving detection sensitivity in low flow velocity high performance liquid chromatographic apparatus.

Abstract: The present invention provides a novel compound exhibiting an excellent suppressing effect to cell injury caused by radicals and neurotoxicity induced by excitatory nuerotransmitters such as glutamate. Specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Z represents a bivalent organic group and the like of from 2 to 3 carbon atom(s) which may have a substituent; and R3 represents a carboxyl group and the like.

Abstract: An elution test method measures the elution process of a specific component in a process where a preparation containing at least the specific component subject to a change with time in chemical properties after elution and an impurity component not subject to a change with time in chemical properties after elution is eluted into a test liquid. The method obtains a ratio of absorbance k of the impurity component and a ratio of absorbance k? of the specific component at two isosbestic point wavelengths ?1, ?2 in a spectrum including the specific component and its decomposed matter, and calculates at least one of the absorbances A1(t), A2(t) of said specific component by using k×C2(t)?C1(t)=k×A2(t)?A1(t) and A1(t)/A2(t)=k? from the absorbance C1(t), C2(t) at said two isosbestic point wavelengths ?1, ?2 measured at the plural time points t in the elution process of said preparation, and converts the result to an elution concentration.

Abstract: The present invention provides a bilayer dispersing agent for a sustained-release preparation, which contains a non water-soluble solvent and an aqueous solvent, and a sustained-release preparation wherein a microcapsule containing a physiologically active substance is dispersed in the aforementioned dispersing agent. When this preparation is subcutaneously administered, the initial release of a physiologically active substance immediately after administration is strikingly suppressed, a constant amount of a physiologically active substance is released for a long period of time from immediately after administration, superior dispersibility is afforded, and the preparation can readily pass through a needle as an injection.

Abstract: The present invention relates to a pharmaceutical composition containing a cycloalkene compound a salt thereof or a prodrug thereof, and a nonionic surfactant and/or a cyclodextrin derivative readily soluble in water, and a method for improving solubility, stability or coloring property of the compound, a salt thereof or a prodrug thereof.